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ABSTRACT 
Type 2 diabetes (T2D) is an inflammatory disease associated with infiltration of 
immune cells into various tissues and increased levels of inflammatory factors 
including Interleukin-1 β (IL-1β). In pancreatic islets elevated glucose levels 
stimulate IL-1β production resulting in impaired function and survival of β cells. 
Blockade of IL-1β improves T2D, pointing on a major role for IL-1β in the 
development and T2D. While the deleterious role of chronic activation of the IL-1 
system in T2D is well documented, little is known about its potential physiological 
role(s).  
The aim of the present study is to reveal the physiological role of inflammation 
and specifically of IL-1β in metabolism.  
In vivo acutely administered IL-1β dose dependently induced insulin secretion 
even at IL-1β concentrations in the circulation that are below the detection limit. 
Together with glucose IL-1β promotes insulin secretion via parasympathetic nerve 
stimulation. In vitro IL-1β had a dual effect on glucose stimulated insulin 
secretion: it was beneficial at low doses and deleterious at high doses. The 
endotoxin lipopolysaccharide (LPS) strongly induced IL-1β, stimulated insulin 
secretion and improved glucose tolerance. Interestingly, the improvement of 
glucose tolerance was not only a consequence of increased insulin levels but was 
also due to direct IL-1β mediated glucose uptake into various tissues. One of the 
compartments responding to IL-1β with elevated glucose uptake was the cells of 
the immune system, mainly macrophages. We further show that macrophages 
significantly contribute to IL-1β mediated glucose disposal from the circulation. In 
addition, this work provides evidence for a role of insulin in mounting an immune 
response. Indeed, insulin increased the secretion of IL-1β via the NACHT, LRR 
and PYD domains-containing protein 3  (NLRP3) inflammasome preferentially in 
inflammatory M1 macrophages but not from alternatively activated M2 
macrophages. In line with this response, M1 macrophages expressed higher 
levels of insulin receptors than naïve or M2. Further, insulin had an overall pro-
inflammatory effect in naïve and inflammatory macrophages, which could be 
attributed to increased glucose uptake via the GLUT1 glucose transporter.  
6	  
	   7	  
This study uncovered that insulin and IL-1β stimulate each other. In a 
physiological context IL-1β together with insulin may activate innate immunity in 
order to respond to post-meal intruding gut microbiota or to cope with infections. 
Indeed, acute phase inflammatory responses following an infection are 
associated with insulin resistance increasing the demand for insulin. Elevated 
insulin levels together with IL-1β may supply glucose to the immune compartment 
to provide the energy required for its activation. Hence elevated insulin levels in 
obesity may contribute to the development of insulin resistance and worsening of 
T2D by chronically activating the immune system. 
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1 INTRODUCTION  
1.1. Overview 
The majority of cases of diabetes (80%) are attributable to the increasing 
incidence of obesity. Nutrient excess and adiposity activate pathways implicated 
in the development of insulin resistance and induce inflammation1. Chronic 
inflammatory conditions have a major impact on the development of metabolic 
diseases including diabetes. However, the physiological role of inflammation in 
metabolism and short-term metabolic stress is still unclear.  
The deleterious role of IL-1β in T2D is well-described2. IL-1β is one of the major 
cytokines governing inflammation, but it also has a role in the pathology of insulin 
secretion3. Whereas, In vitro, chronic or high doses of IL-1β directly impair insulin 
secretion, acute exposure or low doses improve it4. The focus of this work is to 
understand the in vivo consequences on the effect of systemic increase in IL-1β 
on insulin secretion and action, and its consequence on glucose metabolism.  
1.2 Alpha (α) and beta (β) cells of the pancreas and their hormones 
Insulin and glucagon, the two counteracting hormones of the endocrine pancreas, 
are responsible for maintaining blood glucose levels in a narrow range. Insulin is 
produced by pancreatic islet β-cells and is secreted in response to rising blood 
glucose concentrations. By mediating glucose uptake in the periphery and 
enhancing glycogen synthesis in the liver, insulin promotes energy storage in the 
fed state and thus maintains blood glucose levels in the normal range. In contrast, 
glucagon is secreted by pancreatic α-cells when blood glucose levels drop. 
Glucagon stimulates glycogenolysis and gluconeogenesis in the liver thereby 
preventing hypoglycaemia. Therefore glucagon is essential for maintaining 
glucose homeostasis in the fasting state. 
 
1.3 Insulin secretion 
 
Insulin, the key hormone in regulating glucose metabolism, is secreted from 
pancreatic β-cells. The process of its secretion is a highly dynamic and regulated 
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by multiple factors. Nutrient status, hormonal factors, and neuronal factors5, 6, 7, 
regulate insulin secretion at multiple levels: at the level of single β-cells, the 
pancreatic islet, the whole pancreas, and the intact organism. Hence, in vivo, the 
dynamics of insulin secretion is the consequence of an integration of all of these 
systems. 
Stimulus-secretion coupling is an essential biologic event in glucose regulated 
insulin secretion in pancreatic β-cells. Ca2+, ATP, cAMP, and phospholipid-
derived signals such as diacylglycerol (DAG) and inositol 1,4,5-triphosphate (IP3) 
are the major intracellular signals during insulin secretion8, 9.  
Glucose-stimulated insulin secretion (GSIS) is the principal mechanism of insulin 
secretion. Glucose is transported into the β-cell mainly by GLUT2 glucose 
transporters, and then metabolized, leading to an increase of the  ATP/ADP ratio, 
closure of ATP-sensitive K+ (KATP) channels, depolarization of the β-cell 
membrane, and opening of the voltage-dependent Ca2+ channels (VDCCs), 
resulting in Ca2+ influx10. The resulting rise in intracellular Ca2+ concentration in 
the β-cell triggers insulin secretion. In addition, there is also a KATP channel–
independent pathway that amplifies the effects of Ca2+ on exocytosis and does 
not require an additional increase in intracellular Ca2+ concentration11. 
1.3.1 Islet G coupled receptors mediated insulin secretion 
Various signals regulate glucose stimulated insulin secretion, including hormones 
(glucagon-like peptide-1; GLP-1, and glucose-dependent insulinotropic 
polypeptide; GIP), neurotransmitters (e.g. acetylcholine; ACh) and nutrients (e.g. 
free fatty acids; FFAs). These factors signal through guanine nucleotide-binding 
protein (G protein)-coupled receptors (GPCR) to enhance GSIS. The islet GPCR 
mainly couple to adenylate cyclase and to phospholipase C (PLC). 
1.3.1.1 Acetylcholine-potentiated GSIS 
ACh, the major neurotransmitter of the peripheral parasympathetic nervous 
system, is known to facilitate the release of insulin in a glucose-dependent 
fashion. ACh is released from intra-pancreatic parasympathetic (vagal) nerve 
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endings during the pre-absorptive and, most likely, also during the absorptive 
phase of feeding. Of note, vagal nerves release at least five different 
neurotransmitters.  Muscarinic ACh receptor subtypes (M1–M5) are widely 
expressed in a complex and overlapping pattern in many peripheral tissues and 
most regions of the brain. In β-cells the M3 muscarinic ACh receptor is the major 
muscarinic receptor expressed. β-cell specific M3 muscarinic receptor ko mice 
have impaired glucose tolerance and impaired insulin secretion and islets isolated 
from these mice have impaired GSIS12. In β-cells ACh activates several signal 
transduction pathways. One of the major pathways targeted by ACh is PLC, 
which mainly generates IP3 and DAG. They are potent PKC activators, which lead 
to an increased efficiency of free cytosolic Ca2+ in the stimulation of exocytosis of 
insulin granules. ACh also depolarizes the plasma membrane of β-cells by  Na+- 
or nonspecific cationic-dependent mechanisms. This depolarization is small and 
reaches the threshold for the activation of voltage-dependent Ca2+ channels only 
if the plasma membrane is already depolarized by secretagogues such as 
glucose. The glucose dependence of this depolarization largely contributes to the 
glucose-dependence of ACh stimulated insulin secretion. The insulinotropic effect 
of ACh results from two mechanisms: one involves a rise in intracellular calcium 
concentration and the other involves a marked, PKC-mediated increase in the 
efficiency of Ca2+ to stimulate exocytosis of insulin vesicles. 
1.3.1.2 Incretin-potentiated GSIS 
Incretin hormones are polypeptides released from endocrine cells in response to 
nutrient ingestion, which stimulate insulin secretion in a glucose dependent 
manner. Both GLP-1 and GIP are incretin hormones. 
GLP-1 is produced mainly in the distal jejunum, ileum and colon by L cells. GIP is 
produced in the proximal small intestine (duodenum and jejunum) by the intestinal 
K cells. The most studied incretin effect is the stimulation of insulin secretion by 
GLP-1. It induces insulin secretion and biosynthesis via GLP-1 receptor 
activation, followed by activation of adenylate cyclase (AC) and increased cAMP 
production. In addition, β-cell apoptosis is inhibited and ER stress is reduced 
through activation of AC whereas β-cell proliferation and neogenesis are 
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mediated via phosphatidylinositol-3 kinase (PI3K) activated pathways. 
Furthermore, GLP-1 inhibits glucagon secretion from the α-cells in vivo. This 
inhibitory effect may involve direct binding of GLP-1 to its receptor on α-cells, 
alternatively GLP-1 may inhibit glucagon secretion indirectly by stimulating insulin 
and somatostatin secretion.  
Figure 1. Model of insulin secretion. Glucose-induced insulin secretion and its potentiation 
constitute the principal mechanism of insulin release. Glucose is transported by the glucose 
transporter (GLUT) into the pancreatic β-cell. Metabolism of glucose increases ATP production 
(and the ATP-to-ADP ratio), closing the KATP channels, resulting in membrane depolarization 
(ΔΨ), opening of the voltage-dependent Ca2+ channels (VDCCs), and Ca2+ influx, which triggers 
insulin granule exocytosis. Insulin granule exocytosis is also regulated by hormones (GLP-1/GIP) 
and neurotransmitters (ACh), which generate intracellular signals such as cAMP, diacylglycerol 
(DAG), and inositol triphosphate (IP3). Image adapted from13
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1.4 Type 2 diabetes 
1.4.1 Overview 
In individuals suffering from T2D the pancreatic β-cells fail to produce sufficient 
insulin to compensate for peripheral insulin resistance, resulting in hyperglycemia. 
Obesity is associated with insulin resistance and is thus a risk factor for 
developing T2D. The lack of responsiveness to insulin eventually increases the 
demand for insulin and in order to adapt, the functional β cell mass in the 
endocrine pancreas increases. Nevertheless, this adaption can fail, eventually 
leading to diabetes.  
The pathophysiology of T2D is characterized by impaired β-cell secretory function 
and decreased β-cell mass due to increased apoptosis14. In addition, T2D is 
accompanied by morphological alterations of pancreatic α-cells, increased α-cell 
mass and dysregulation of glucagon secretion. Recently, innate immunity and 
inflammatory processes were shown to contribute to the development of T2D. 
1.4.2 T2D as an auto-inflammatory disease 
Auto-inflammatory diseases are characterized by sterile inflammation 
predominantly mediated by the cells and molecules of the innate immune 
system15. Some auto-inflammatory diseases are attributed to a dysfunctional 
monocyte caspase 1 activity which is responsible for the conversion of 
cytoplasmic pro-IL-1β to its active, secreted form; Blocking IL-1β results in a rapid 
and sustained reduction in the severity of most auto-inflammatory diseases 
including T2D16.  
Pancreatic islet inflammation plays a role in the development and progression of 
T2D. Islets of T2D patients display clear signs of inflammatory processes, such 
as cytokines, apoptosis markers, immune cell infiltration and fibrosis17, 18, 19. In 
addition, free fatty acids and glucose induce endoplasmatic reticulum (ER) stress 
and a pro-inflammatory pattern that results in dysfunctional pancreatic islet20, 21, 22,
23. Thus the combination of dyslipidemia, hyperglycemia and islet amyloidosis24, 25 
in T2D is probably the driving force behind this inflammatory response. 
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IL-1β not only has a deleterious effect on insulin secretion but also contributes to 
the development of insulin resistance. Interestingly, IL-1β induced insulin 
resistance in adipocytes26 and the NLRP3 inflammasome which regulates IL-1β 
processing and secretion contributes to obesity induced insulin resistance27. In 
addition, NLRP3-derived IL-1β induced by FFAs prevented normal insulin 
signaling in insulin target tissues leading to insulin resistance28 
All together these data support the concept that T2D is an inflammatory disease.  
   
1.5 Innate immunity and inflammatory processes 
1.5.1 Overview 
The innate immune system serves as the first line of defense to protect the body 
from infection or irritation in a non-specific manner. This means that the cells of 
the innate system recognize and respond to pathogens in a generic way29. 
Inflammation is one of the first reactions of the innate immune system and is 
stimulated by various factors released by injured cells. Inflammation serves to 
protect against stressors, and to restore tissue and organism homeostasis. The 
process of acute inflammation is initiated by cells, mainly macrophages that are 
present in all tissues. These cells present receptors on the cell surface or within 
the cell, known as pattern recognition receptors (PRRs). These receptors 
recognize molecules that are shared by different pathogens, collectively termed 
as PAMPs (pathogen-associated molecular patterns)30. At the onset of stress, 
these cells undergo activation e.g. Toll like receptors (TLR) bind LPS, and release 
inflammatory mediators responsible for the clinical signs of inflammation31. This 
process is largely driven by IL-1β, one of the first cytokines discovered 4. 
Prolonged activation of the immune system may eventually promote the 
development of a chronic inflammatory disease. Interestingly, over-nutrition and 
obesity lead to such a chronic activation of the innate immune system, eventually 
leading to metabolic diseases32, 33, 34, 35, 36. Indeed, acute-phase proteins, cytokine 
and chemokine levels as well as immune cell types and numbers are altered in 
the circulation and in various tissues of patients with metabolic diseases19, 37. A 
crucial role in the initiation of an innate immune response and of auto 
inflammatory diseases including T2D is attributed to macrophages, the main 
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source of IL-1β in the body. 
 
1.5.2 Macrophages 
Macrophages are distributed throughout the body. In some tissues, they 
represent 10 – 20% of all cells and become highly specialized cells such as 
Kupffer cells in the liver, osteoclasts in the bone or microglia in the brain. 
Macrophages are versatile cells and can adopt specialized functions at particular 
tissue locations. Macrophages are derived from circulating precursors, the 
monocytes. Circulating monocytes are released from the bone marrow as non-
differentiated cells, circulate in the blood for a few days in a process called rolling 
and are poised to rapidly extravate to inflamed tissues. Upon local inflammation, 
circulating monocytes undergo extravasation, which involves adhesion and 
transmigration into a target tissue. Upon infiltration into the inflamed tissue, 
monocytes readily differentiate into mature macrophages. Stimulation of 
macrophages with cytokines such as IFNγ alone or together with other cytokines 
(e.g. TNFα) or bacteria derived stimuli (e.g. LPS) promotes the maturation of 
"classically" activated macrophages termed M1. These cells are characterized by 
the production of of high levels of toxic intermediates (e.g. reactive oxygen 
species, nitric oxides), a high capacity to present antigens and high secretion 
levels of inflammatory cytokines. M1 macrophages are the main source for IL-1β 
in the body. In contrast, various signals (e.g. IL-4, IL-13) induce “alternative” 
maturation termed M2 macrophages. These cells are able to down-tune 
inflammatory responses, scavenge debris, and promote angiogenesis and tissue 
remodeling. 
Recently, many studies focused on molecules that could play a role in 
macrophage polarization, such as cytokines, transcription factors or enzymes. 
Interestingly, as macrophages switch from a quiescent (naïve) to an activated 
state, their metabolic activity is modified. Recent evidence suggests that immune 
cells adopt specific metabolic signatures38, 39. Metabolic changes in cells that 
participate in inflammation, such as activated macrophages (and T-helper 17 
cells), include a shift towards enhanced glucose uptake, glycolysis and increased 
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activity of the pentose phosphate pathway. In contrast, anti-inflammatory cells, 
such as M2 macrophages (and regulatory T cells and quiescent memory T cells), 
have lower glycolytic rates and higher levels of oxidative metabolism. This is 
presented in the following figure. An important question in the field of 
“immunometabolism” is whether metabolic pathways themselves can alter 
immune cell differentiation and thus have direct effector function. Glucose is a 
critical component in the pro-inflammatory response of macrophages. In pro-
inflammatory polarized M1 macrophages, GLUT1 (SLC2A1) is the primary rate 
limiting glucose transporter and metabolic reprogramming via increased glucose 
availability modulates macrophage inflammatory response40. This suggests that 
T2D hyperglycemic milieu may act as a driving force of M1 macrophage 
polarization.  
 Figure 2 Metabolic profile and typical markers of polarized macrophages: Classically 
activated macrophages (M1) induce an aerobic glycolytic (will be reflected in extracellular 
acidification rate; ECAR) program that results in lactate production and increased levels of 
intermediates of the Krebs cycle. The hypoxia-inducible factor (HIF) 1α transcription factor also 
becomes activated and can drive production of pro-inflammatory cytokines. Alternatively activated 
macrophages (M2) trigger a metabolic program including the electron transport chain as well as 
fatty acid β-oxidation (that will be reflected in oxygen consumption rate; OCR). Taken from41. 
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1.6 Interleukin-1 
1.6.1  Overview 
 
The IL-1 family of cytokines consists of 11 known members that are encoded by 
distinct genes and includes IL-1α, IL-1β, and the IL-1 Receptor antagonist (IL-
1Ra). The major role of IL-1 type cytokines is to control pro-inflammatory 
reactions in response to tissue injury42 - either due to recognition of PAMPs (e.g. 
the bacterial wall product LPS) or of danger associated molecular patterns 
(DAMPs; e.g. uric acid) by a target cell. IL-1α is a membrane-anchored protein 
that upon its release, signals through autocrine or juxtracrine mechanisms. IL-1β 
is processed from its zymogen form (pro-IL-1β) by caspase-1 (IL-1β converting 
enzyme) and upon secretion acts in a paracrine or systemic manner. Of note, IL-
1β is predominantly produced by macrophages and monocytes, but to a much 
lesser extent also by other cell types such as epithelial cells, fibroblasts, 
endothelial cells and pancreatic islets including the insulin expressing beta cells21, 
43. Secretion of IL-1β is a highly regulated process that requires the formation of a 
protein complex called the inflammasome44. There are several variations of this 
multi-protein complex, The NLRP3 inflammasome is the most fully characterized 
form. The NLRP3 inflammasome contains the adaptor protein apoptosis-
associated specklike protein (ASC), the proinflammatory caspase, caspase-1 and 
NLRP3. NLRP3 belongs to the nucleotide-binding oligomerization domain (NOD)–
like receptor (NLR) family of PRRs. Upon activation, NLRP3 is thought to 
oligomerize via homotypic interactions between NACHT (NTPase) domains and 
by presenting clustered pyrin (PYD) domains enabling an interaction with the PYD 
domain of ASC. ASC assembly, in turn, presents clustered caspase activation 
and recruitment domains (CARDs) for interaction with the CARD of procaspase-1. 
Procaspase-1 clustering enables auto-cleavage and activation; activated 
caspase-1 can cleave other cytosolic targets, including IL-1β. Thus unlike IL-1α 
the expression of IL-1β mRNA is necessary but not sufficient to activate IL-1 
signaling16.  
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1.6.2 Interleukin-1 signaling 
IL-1 has two isoforms, IL-1α and IL-1β. Both bind to the same cellular receptor, 
the Type 1 IL- 1 receptor (IL-1R1) to induce signaling. Upon receptor 
engagement, IL-1R1 forms a heterodimer with its co-receptor IL-1 receptor 
accessory protein (IL-1RAcP). IL-1RAcP cannot bind directly to IL-1 but is 
essential for IL-1-mediated signaling. Binding of IL-1 to this receptor complex 
leads to the activation of the transcription factor NF-κB through different signaling 
mechanisms. IL-1 receptor-associated kinases, IRAK-1, IRAK-2 and IRAK4 have 
been implicated in the activation of NF-κB. IRAKs function as adapter proteins 
and protein kinases to transmit downstream signals. This leads to the recruitment 
of TNF receptor associated factor 6 (TRAF6) to the IL-1 receptor complex via an 
interaction with IL-1RAcP. Oligomerization of TRAF6 and subsequent formation of 
TAK1 and MEKK3 signaling complexes relays the signal leading to NF-kB 
activation (see figure below).  
In addition, activation of mitogen activated protein kinases, including JNKs and 
p38 MAPK through various MAP2Ks also plays an important role in mediating IL-
1 responses by enhancing transcription through the activator protein-1 (AP-1) 
transcription factor.  
These signaling events co-operatively induce the expression of IL-1 target genes 
such as IL-8 (KC/CXCL1 in mice) and IL-6.  
IL-1 signaling is regulated by various mechanisms. The IL-1 family member IL-
1Ra binds with a similar affinity to the IL1-R1 receptor as the agonistic ligands IL-
1α and β, but it is incapable of activating the signaling response. The type 2 IL-1 
receptor is a decoy receptor that binds to IL-1α and β but lacks signaling 
capacity. The naturally occurring 'shed' domains of the extracellular IL-1 receptor 
chains (soluble IL-1R1, IL-1R2 and IL- 1RAcP) also act as inhibitors of IL-1 
signaling. In the cell, IL-1R binds to toll- interacting protein (TOLLIP), which 
results in the inhibition of IRAK1 and subsequent targeting of the internalized IL-
1R to endosomes leading to efficient degradation. Other mechanisms such as 
p38MAPK mediated phosphorylation of TAB1 which results in the inactivation of 
TAK1, and expression of genes including MAPK phosphatase 1 (MKP-1) and 
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Inhibitor of kappa B alpha (NFKBIA) that inhibit IL-1 signaling components also 
serve as negative regulators of IL-1 signaling as shown in the following figure. 	  
	  	  
Figure 3. Scheme for IL-1 signaling. Upon binding of IL-1β or IL-1α to IL-1R1 and IL-1RAcP, 
MyD88 is recruited, IRAKs are being phosphorylated leading to formation of protein complex that 
activate NF- kappa B or AP-1 via degradation of I kappa B or activation of JNK and p38 
respectively. Resulting in cytokine expression. Negative regulation is done in multiple levels, from 
receptor antagonist (IL-1Ra) and decoy receptors (IL-1R2 or soluble receptors) to inhibition of 
IRAK by TOLLIP, TAK1 by TAB1, MKK by MKP-1 and NF-kappa B by NFKBIA in addition IL-1R1 
signaling results in receptor internalization mediated by TOLLIP. 
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1.6.3 Interleukin-1β in T2D 
To describe the role of IL-1β in T2D, this chapter is divided to 2 parts, one part 
focuses on IL-1β in obesity and insulin resistance and the other one on the role of 
IL-1β in islet dysfunction.  
The discovery of protective effects of tumor necrosis factor (TNF) neutralization 
on glucose uptake in obese rats was one of the first observations linking 
inflammation to the development of insulin resistance33. Cytokines such as IL-1β, 
TNF and IL-6 induce the expression of suppressors of cytokine signaling and limit 
inflammatory signals. These suppressors interfere with tyrosine kinases including 
the one of the insulin receptor45. Furthermore, inflammatory signals, including IL-
1β, result in the ubiquination and breakdown of insulin substrates, IRS1 and 
IRS246. In vivo, the importance of IL-1β in metabolic disorders was demonstrated 
by studies showing the crucial role of NLRP3 inflammasome in the development 
of obesity and insulin resistance. Mice deficient for NLRP3 or the pro-IL-1β 
converting enzyme, caspase-1, are protected from diet induced obesity47, have 
improved insulin sensitivity48 and reduced IL-18, interferon gamma (IFNγ) and 
effector T cell numbers in adipose tissue. In obese humans with T2D the 
improved insulin sensitivity upon weight loss is associated with reduced NLRP3 
expression27. In addition, FFAs activate the NLRP3 inflammasome28 by 
increasing reactive oxygen species (ROS) which leads to more cytokine 
production and enhanced insulin resistance. Of note, insulin resistance does not 
result in an overall reduced glucose consumption as other glucose transporter 
(GLUT1) are upregulated in adipocytes treated with IL-1β26, i.e. it is the insulin 
regulated glucose uptake via GLUT4 that is impaired while basal glucose 
consumption is increased, leading to increased ROS production. 
Besides the described effects on insulin sensitivity, inflammation has a role in the 
impairment of insulin secretion. High IL-1R1 expression in insulin producing beta 
cells20 renders them sensitive to the deleterious effects of IL-1β. These include 
the formation of nitric oxide49 followed by induction of the death receptor Fas50 
and necrosis51. Islets treated with high concentrations of IL-1β have impaired 
glucose stimulated insulin secretion and increased beta cell death. Interestingly, 
high concentrations of glucose also induced apoptosis in cultured islets52. Further 
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investigation revealed that glucose induces IL-1β in islets and that the deleterious 
effects of glucose on islet function and survival were diminished when islets were 
treated with IL-1Ra21. These findings were confirmed and extended by the 
discovery showing that high glucose concentrations activate the NLRP3 
inflammasome in islets53. Later, other metabolites and proteins typically altered in 
T2D state have been described to act as activators of the NLRP3 
inflammasome24, 28.         
All of the above explains why out of the 11 members of the IL-1 family, IL-1β had 
emerged as the primary therapeutic target in auto inflammatory diseases54, 55.  
However, the observation of high expression of IL-1R1 in β cells also suggests a 
physiological function of IL-1β in pancratic beta cells that has been neglected in 
the past years. Indeed old publications demonstrate a dual role of IL-1β on insulin 
release of pancreatic islets4. Furthermore, low dose treatment with IL-1β induced 
beta cell proliferation and secretion in human islets52 also hinting to more complex 
roles of IL-1β in islets. This work focuses on the physiological role of IL-1β in 
insulin secretion and its consequences. 
 
1.7 Aim of study 
Numerous studies associated IL-1β with pathological outcomes such as impaired 
β-cell function and survival, however, little is known about its acute, physiological 
role in vivo in metabolism and in the development of diabetes or other auto 
inflammatory diseases. 
The aim of this study was to investigate the acute effects of exogenous and 
endogenously produced IL-1β on glucose metabolism in mice and on related 
parameters such as insulin secretion and insulin resistance. Inflammatory 
processes and activation of the immune response require major changes in the 
metabolic profile of immune cells e.g. increased glycolytic capacity. Since both, 
glucose, as a main fuel for an immediate immune response, and insulin, the main 
regulator of glucose homeostasis, are elevated in the metabolic syndrome, we 
speculated that there might be a link between insulin, glucose metabolism and the 
activation of the immune system. The aim of the present work is to study this 
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possible link, specifically between IL-1β and insulin in glucose metabolism and 
initiation of inflammation. 
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The deleterious role of chronic activation of the IL-1β system in type 2 diabetes and other 
metabolic diseases is well documented. However, little attention has been paid to a possible 
physiological role of IL-1β in the regulation of glucose metabolism. Here we show that acute 
injections of IL-1β strongly induced insulin secretion and improved glucose disposal in normal, 
obese and diabetic mice. This insulin secretagogue effect was potentiated by glucose and 
involved neuronal stimulation. LPS induced similar effects but not in the presence of the IL-1Ra 
or in mice deficient for the NLRP3 inflammasome. IL-1β alone and together with insulin increased 
glucose uptake into muscle, adipose tissue and in the immune compartment, mainly in 
macrophages. In polarized M1 macrophages, insulin reinforced a pro-inflammatory pattern via its 
upregulated receptors, elevated AKT phosphorylation, increased glycolytic activity and 
increased inflammasome-mediated IL-1β secretion. Our findings identify a physiological role for 
IL-1β and insulin in the regulation of both metabolism and immunity.  
 
INTRODUCTION 
 
Activation of the innate immune system is an initial 
response of the body to infections and injuries. The 
resulting inflammation aims at protecting against 
stressors, and at restoring tissue and organism 
homeostasis. This process is largely driven by 
interleukin-1β (IL-1β), one of the first described 
cytokines4. However, prolonged activation of the 
immune system may eventually promote the 
development of a chronic inflammatory disease. 
Increasing evidence shows that over-nutrition and 
obesity lead to such a chronic activation of the innate 
immune system and subsequent metabolic diseases32, 
33, 34, 35, 36. Indeed, acute-phase proteins, cytokine and 
chemokine levels as well as immune cell types and 
numbers are altered in the circulation and in various 
tissues of patients with metabolic diseases19, 37. A 
critical sensor of nutrient overload is the NACHT, LRR 
and PYD domains-containing protein 3 (NLRP3) 
inflammasome, which promotes the maturation of IL-1β 
in various metabolic disorders. This is the case for uric 
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acid crystals which activate the NLRP3 inflammasome 
in gout56, for cholesterol crystals which induce it in 
atherogenesis57, and for glucose, fatty acids, and islet 
amyloid which contribute to impaired insulin secretion 
and action via NLRP3 in type 2 diabetes21, 24, 27, 28, 48. 
Importantly, a causal link between IL-1β-induced 
inflammation and these metabolic diseases has been 
demonstrated by various genetic and pharmacological 
approaches in animal models47, 53, 58, 59, 60, 61 and 
therapeutic interventions in humans54, 62, 63, 64, 65, 66. 
While these studies shed light on the pathological 
aspects of IL-1β and chronic inflammation in 
metabolism, the expected (acute) physiological role of 
IL-1β in metabolic control remains largely unexplored.  
In response to an infection, a massive expansion and 
activation of the immune system occurs. To cope with 
the energy requirement of this process profound 
changes in the metabolism of immune cells take 
place40, 67, 68, 69. Beyond supplying energy, nutrients can 
also act as cell signaling molecules in the activation of 
the immune system. Indeed, elevated glucose levels 
and metabolites such as succinate may drive 
production of IL-1β in macrophages21, 53, 70. 
The main immediate source of energy in the body is 
glucose, which is primarily regulated by insulin. 
Interestingly, the insulin-producing β-cells express the 
highest level of IL-1 receptor compared to other tissues 
and are highly sensitive to IL-1β20, 71, 72. While a large 
body of in vivo and in vitro data demonstrate a 
deleterious role of high dose and long-term IL-1β 
exposure on islet function and mass, a few mainly in 
vitro observations hint to a possible beneficial role of IL-
1β in the function and survival of β-cells4, 52, 73. 
Therefore, we hypothesized that an acute increase in 
IL-1β has a physiological role in whole body glucose 
homeostasis that is to recruit the energy needed to 
activate the innate immune system. We provide 
evidence that in vivo an acute increase in IL-1β shifts 
glucose disposal from the circulation to classical insulin 
sensitive tissues and to the immune compartment partly 
via potent neuronal stimulation of insulin secretion. In 
macrophages, IL-1β and insulin promote glucose 
uptake via the glucose transporter GLUT1, and 
increase glucose metabolism and cytokine production. 
Interestingly, insulin stimulates IL-1β production in 
polarized macrophages via glucose uptake and the 
NLRP3 inflammasome and therefore directly modulates 
the immune system. 
 
RESULTS 
 
IL-1β is a potent insulin secretagogue and improves 
glucose disposal in normal, obese and diabetic 
mice. 
In order to test the acute in vivo effects of IL-1β we first 
evaluated the pharmacokinetic of increasing 
concentrations of intraperitoneal (ip) IL-1β injections in 
normal mice. Basal circulating IL-1β levels were 2.8 ± 
2.5 pg/ml and peaked after 15 minutes at 9.0 ± 2.0, 
12.7 ± 7.7, 46.1 ± 12.1 and 178.5 ± 28.7 pg/ml after 
injection of 0.1, 0.25, 0.5 and 1 µg/kg IL-1β, 
respectively (Fig. 1a, Supplementary Fig. 1a). Based on 
these data we injected IL-1β 18 minutes before an ip 
glucose tolerance test (ipGTT) in subsequent studies. In 
a dose dependent manner, IL-1β strongly induced 
insulin secretion along with a profound improvement of 
glucose clearance (peak insulin concentration in plasma 
2.0 ± 0.2, 2.1 ± 0.3 and 3.6 ± 0.3 ng/ml following 0.25, 
0.5 and 1 µg/kg IL-1β respectively; Fig. 1b,c). Of note, 
although the lowest injected dose of 0.1 µg/kg IL-1β 
only marginally increased the concentration of 
circulating IL-1β, it was sufficient to significantly elevate 
insulin levels, demonstrating the potency of IL-1β 
(Supplementary Fig. 1b). Since insulin resistance is 
associated with systemic inflammation33, we assessed 
insulin sensitivity with an ip insulin tolerance test (ITT) 
and during hyper-insulinemic-euglycemic clamp studies. 
Following an acute ip injection of 1 µg/kg IL-1β, insulin 
sensitivity and hepatic glucose production remained 
comparable to the control group (Fig. 1d-f, 
	   35	  
Supplementary Fig. 1c,d). Because diet induced obese 
(DIO) mice have an impaired glucose tolerance, we 
tested whether acute IL-1β is still beneficial in this 
context. Mice fed with a high fat diet for 24 weeks were 
injected with 1 µg/kg IL-1β prior to an ipGTT. Treated 
mice had improved glucose tolerance along with a 
strong stimulation of insulin secretion (Fig. 1g,h). As a 
second model of impaired glucose metabolism, 16 
week old db/db mice were injected ip with 1 µg/kg IL-1β 
prior to an ipGTT. Even in these severely insulin 
resistant animals, IL-1β improved glucose tolerance 
and strongly increased insulin secretion (Fig. 1i,j). To 
demonstrate that the observed effects of IL-1β are 
mediated by the IL-1 receptor signal transduction 
pathways, we used IL-1 receptor-associated kinase-4 
(IRAK-4) deficient mice. In contrast to wild-type mice 
(not shown), IRAK-4 deficient mice injected with IL-1β 
before an ipGTT showed no change in blood glycaemia 
and no improvement in insulin secretion (Fig. 1k,l). Next 
we assessed the insulin secretagogue capacity of IL-1β 
or glucose alone compared to the combination of both. 
Injection of IL-1β or glucose alone led to a small 
induction of insulin secretion and a mild decrease in 
blood glucose concentration. In contrast, IL-1β 
combined with glucose strongly potentiated the effect of 
either glucose or IL-1β alone. This effect of the 
combination was more than additive (Fig. 1m-o). To 
assess the direct effect of IL-1β on insulin secretion, we 
first identified the IL-1 receptor type 1 and detected it in 
a subpopulation of β-cells (Fig. 1p) at a much higher 
expression level than in islet resident immune cells (Fig. 
1q). In vitro in isolated mouse pancreatic islets, the 
presence of IL-1β for 30 minutes at 2.8 mM glucose 
(priming) had a biphasic effect on subsequent glucose 
stimulated insulin secretion (16.7 mM): low 
concentrations of IL-1β up to 0.5 ng/ml increased, 
whereas 2 ng/ml IL-1β blunted glucose stimulated 
insulin secretion (Fig. 1r). IL-1β priming also improved 
glucose stimulated insulin secretion of human islets at 
0.5 ng/ml (Fig. 1s) and at 1 ng/ml in the human β-cell 
line ENDOC (Fig. 1t). Therefore, IL-1β priming also 
potentiates glucose stimulated insulin secretion in vitro. 
Of note, the IL-1β secretagogue effect was much 
stronger in vivo than in vitro, pointing to additional 
indirect effects of IL-1β on insulin secretion and tissue 
glucose uptake.  
 
Endogenous IL-1β plays a role in insulin secretion  
Next we tested whether the effects of exogenous IL-1β 
on insulin secretion and glucose disposal are 
physiological or merely pharmacological by inducing 
endogenous IL-1β production with LPS. We first 
measured the kinetics of LPS-induced IL-1β secretion. 
Injection of 1 mg/kg of LPS increased circulating IL-1β 
levels and reached a peak after 3 hours (Fig. 2a), which 
was paralleled by a drop in blood glucose levels (Fig. 
2b) and an increase in insulin concentration (Fig. 2c). In 
contrast, LPS injection in IL-1β deficient mice resulted 
in blunted insulin secretion compared to wild type mice 
(Fig. 2d). To substantiate the role of endogenous IL-1β, 
we then injected LPS in chow and high fat diet fed mice 
and performed an ipGTT. Similar to IL-1β, LPS strongly 
improved glucose tolerance and stimulated insulin 
secretion (Fig. 2e,f). In the presence of the IL-1 receptor 
antagonist (IL-1Ra; Fig. 2g) or in mice deficient for the 
NLRP3 inflammasome (Fig. 2h), the LPS-induced 
insulin secretory effect was almost completely blocked. 
Finally, since obesity is associated with elevated IL-
1β27, we investigated in obese mice the effect of 
endogenous IL-1β and evaluated its effect on islet 
function by acute IL-1 antagonism. Acute injections of 
IL-1Ra resulted in lower fasting insulin levels in high fat 
fed mice (Fig. 2i) without changing insulin sensitivity or 
hepatic glucose production (Fig. 2j, Supplementary Fig. 
1e,f). Similarly, acute IL-1Ra reduced basal insulin 
levels in db/db mice (Fig 2k). Altogether, this suggests a 
physiological role of endogenously produced IL-1β in 
the regulation of insulin secretion under various 
conditions.  
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In vivo, only prolonged administration of IL-1β 
impairs glucose metabolism 
The role of IL-1β in islet failure and insulin resistance in 
patients with type 2 diabetes is well established36. Due 
to the unexpected above described beneficial effects of 
acute IL-1β injections, we investigated under which 
conditions IL-1β becomes deleterious in vivo. First we 
tested the response to a higher dose of IL-1β (10 
µg/kg), given either acutely as described above or for 5 
consecutive days. Both treatments improved glucose 
tolerance during ipGTT to a similar level (Fig. 3a), 
although the mice injected for 5 days displayed a 
tendency to less pronounced improvement of insulin 
secretion compared to the single injection (Fig 3b). Of 
note, the discrepancy between the similar glucose 
lowering effects at different circulating insulin levels 
pointed to insulin independent IL-1β effects on glucose 
disposal, as depicted below. As a next step we 
increased the dose of IL-1β to 35 µg/kg for 3 days and 
still observed improved glycaemia induced by IL-1β, 
however, in the absence of stimulated insulin secretion 
(Fig. 3c-d). In order to perform prolonged IL-1β 
applications, we then implanted mini-osmotic pumps 
continuously releasing IL-1β (0.1 µg/kg/day) into mice 
for 31 days. At day 17, continuous subcutaneous 
release of IL-1β slightly improved glucose tolerance 
without effect on insulin secretion (Fig. 3e,f) and after 
31 days of treatment, glycaemia and insulin secretion, 
started to deteriorate (Fig. 3g,h). Finally, we injected 
mice daily with 1 µg/kg of IL-1β for 2 weeks and 
observed impaired glucose tolerance (Fig. 3i,j). To 
verify that IL-1β reached the islets, we isolated them 
and observed increased inflammatory parameters (Fig. 
3k). Thus, only prolonged exposure to IL-1β for several 
weeks impairs glucose metabolism. 
 
Improvement of glycaemia by IL-1β is partly 
mediated via neuronal stimulation of insulin 
secretion and is independent of the incretin system 
To better understand the beneficial role of IL-1β we 
performed oral GTT (oGTT), the physiological way of 
glucose ingestion. Mice were acutely injected with IL-
1β followed by oral gavage of glucose. Similar to the 
ipGTT (Fig. 1b), 1 µg/kg of IL-1β strongly improved 
glucose clearance (Fig. 4a). Surprisingly, insulin levels 
were similar to the control group (Fig 4b). Since acute 
IL-1β did not affect insulin sensitivity according to 
insulin tolerance tests and hyper-insulinemic 
euglycemic clamps (Fig 1d-f), we first considered an 
incretin effect to explain the difference between ip and 
oGTT. Therefore we injected mice with the GLP-1 
receptor blocker exendin 9-39 and repeated the ipGTT. 
As expected, exendin 9-39 alone impaired insulin 
secretion and glucose tolerance, however, it failed to 
block the effect of IL-1β (Fig. 4c,d). Furthermore, 
circulating active GLP-1 was not increased upon acute 
IL-1β (Fig. 4e). To definitively rule out an incretin effect, 
we injected GIP/GLP-1 double receptor KO mice with 
IL-1β and observed the same robust improvement in 
glycaemia and increase in insulin secretion than with 
wild type control mice during an ipGTT (Fig. 4f,g). We 
then hypothesized that IL-1β may stimulate insulin 
secretion via neuronal transmission. Therefore we 
repeated the ipGTT after administration of the 
muscarinic acetylcholine antagonist, atropine, and 
observed an attenuation of the IL-1β effect on insulin 
secretion by 80% without affecting blood glucose levels 
(Fig. 3h-j). Of note, also under this condition insulin 
secretion and changes in blood glucose were 
disconnected, further pointing to additional IL-1β effects 
on glucose disposal. In contrast, darifenacin, a specific 
muscarinic 3 receptor (the isoform expressed in β 
cells74, 75) antagonist that does not cross the blood 
brain barrier, did not prevent the IL-1β effect on 
glucose tolerance and insulin secretion (Fig. 4k,l), 
suggesting a central neuronal effect. Furthermore, in 
isolated human but not mouse islets, atropine 
treatment blocked IL-1β promoted insulin release (Fig. 
4m,n), confirming acetylcholine detection in human 
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islets76. This points to a paracrine effect involving IL-1β 
and acetylcholine in insulin secretion in human but not 
in mouse islets. Interestingly, IL-1β induced mRNA 
expression of vesicular acetylcholine transporter 
(vAChT) in cultured mouse and human islets treated 
with IL-1β in vitro (Fig. 4o,p), and in islets isolated from 
mice chronically injected with the cytokine (Fig 4q). In 
addition, as a model for low-grade chronic 
inflammation, islets isolated from high fat fed mice had 
higher vAChT expression than islets from chow fed 
mice (Fig. 4r). The neuronal role of IL-1β mediated 
insulin secretion was also apparent in mice fed a high 
fat diet, where atropine strongly inhibited the effect of 
IL-1β on glucose tolerance (Fig. 4s,t). To confirm the 
neuronal involvement we used GFRα2 deficient mice 
that lack the parasympathetic innervation in the islets77. 
GFRα2 deficient mice injected with IL-1β displayed a 
weaker improvement in glycaemia and insulin secretion 
as compared to wild type littermates (Fig. 4u,v). 
However, this effect is independent of neurons 
expressing the Glut 2 transporter (Supplementary Fig 
1g). Overall, these data show that improvement of 
glycaemia by IL-1β is partially mediated via neuronal 
stimulation of insulin secretion and is independent of 
the incretin system. 
 
IL-1β promotes insulin independent glucose uptake 
in muscle, fat and immune cells but not in the liver. 
To understand the IL-1β mediated and insulin 
independent decrease in blood glucose (Fig. 4a,b), we 
performed glucose bio-distribution assays, using trace 
amounts of radiolabeled 2-deoxy glucose following an 
injection of 1 µg/kg IL-1β. In the absence of 
metabolizable glucose, IL-1β did not stimulate insulin 
secretion (Fig. 5a). IL-1β increased glucose uptake of 
muscle and adipose tissue but not of the liver (Fig. 5b-
e). In addition, glucose uptake was increased in 
circulating white blood cells and in the spleen (Fig. 
5f,g). We followed up by injections of 35 µg/kg of IL-1β 
in mice for 3 days. This led to elevated numbers of 
peritoneal cells and lymphocytes, and splenomegaly 
along with increased glucose uptake in lymphocytes 
and macrophages (Fig. 5h-l). In order to confirm our ex 
vivo results, we exposed isolated T-cells and 
macrophages to IL-1β and observed an increased 
glucose uptake (Fig. 5m,n). Furthermore, blocking 
endogenously produced IL-1 with IL-1Ra resulted in 
decreased glucose uptake in macrophages (Fig. 5o). 
To further investigate the contribution of immune cells 
to the glucose disposal, we first used T and B cell 
deficient (RAG2 KO) mice. These mice showed similar 
glucose disposal in an oGTT upon IL-1β as their 
littermate controls (Fig. 5p). When we then additionally 
ablated the macrophages in RAG2 KO mice with 
clodronate liposomes (Fig. 5q), the IL-1β effect on 
glucose disposal was impaired, suggesting that 
immune cells contribute to IL-1β-induced glucose 
uptake (Fig. 5r). Thus IL-1β promotes glucose uptake 
selectively in fat, muscle and immune cells, but not into 
the liver and this happens independently of insulin.  
 
Insulin regulates macrophage metabolism and 
stimulates IL-1β via the NLRP3 inflammasome. 
Because IL-1β enhanced glucose stimulated insulin 
secretion (Fig. 1), we hypothesized that insulin may 
contribute to the regulation of the immune system. 
Therefore, we first tested the effect of insulin on 
glucose uptake in naïve peritoneal macrophages. 
Insulin alone induced glucose uptake and this effect 
was additive to IL-1β (Fig 6a). Next we investigated the 
expression of the insulin receptor and found it 
upregulated in the pro-inflammatory M1 macrophages 
whereas it was downregulated in the anti-inflammatory 
M2 compared to naïve macrophages (M0; Fig. 6b; as a 
control for the polarization see mRNA expression of 
CD40, IL-1β and Chi3l3 in the Supplementary Fig. 1h). 
Furthermore, insulin induced AKT phosphorylation in 
naïve M0, to a greater extent in M1 but not in M2 
macrophages (Fig. 6c). In line with this pattern, as 
shown by extra cellular acidification rate (ECAR), 
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insulin treatment increased the glycolytic activity 
selectively in M1 macrophages, while it was not 
stimulated in naïve or M2 macrophages (Fig. 6d). 
Furthermore, insulin increased basal oxygen 
consumption rate (OCR) in M0, but had no clear effects 
on this parameter in M1 and M2 macrophages (Fig. 
6e). Similar to the pattern of insulin receptor expression 
and activation, at mRNA level, insulin promoted an 
overall pro-inflammatory state in M0 and M1 
macrophages and an anti-inflammatory in M2 
macrophages (Fig. 6f). At protein level, insulin induced 
secretion of mature IL-1β preferentially in M1, to a 
much lesser extent in M0 and not in M2 macrophages 
(Fig. 6g). In parallel, upon stimulation with IL-1β, IL-
1Ra was strongly induced in M0, less in M1 and 
remained unchanged in M2 macrophages (Fig. 6h). 
This insulin effect on IL-1β secretion was lost in the 
presence of the glucose transporter GLUT1 (also 
known as Slc2a1) inhibitor fasentin (Fig. 6i). Finally, the 
insulin stimulated effect on IL-1β secretion and cytokine 
mRNA expression was lost in macrophages from 
NLRP3 deficient mice (Fig. 6j,k). Interestingly insulin 
also stimulated the expression of GLUT1 and 
hexokinase II (HKII), the rate-limiting enzyme of 
glycolysis. In addition we detected increased NLRP3 
expression upon insulin treatment (Fig. 6j,k). Overall, 
these data show that insulin directly regulates 
macrophage energy metabolism and function, and 
induces inflammasome mediated IL-1β secretion. 
These effects are dependent on the activity status of 
macrophages. 
 
DISCUSSION 
 
The deleterious effects of IL-1β on islet function and 
survival are well described and IL-1β was frequently 
used as a tool to provoke β-cell demise49, 71, 72. 
Paradoxically, at low concentrations or upon short 
exposure, IL-1β modestly stimulates insulin secretion in 
isolated islets indicating that IL-1β may not only be 
detrimental for β-cells but may have more complex 
biological functions4, 52. A possible physiological role of 
IL-1β in islets is also suggested by our previous 
observation of high levels of IL-1 receptor mRNA 
expression in whole islets20 and in the present study by 
its prominent expression in β-cells. Furthermore, 
injections of IL-1β shortly prior to a glucose bolus 
massively improved glucose disposal, supporting 
previous findings with pharmacological doses of IL-
1β73, 78. We show that this was due to increased insulin 
secretion via activation of neurons involved in the 
release of insulin and due to direct IL-1β-mediated 
glucose uptake. Of note, IL-1β increased glucose 
uptake in muscle, fat and immune tissues but not in the 
liver and without changes in insulin sensitivity. The 
physiological relevance of these findings was 
demonstrated by LPS-induced endogenous IL-1β 
secretion, which was equally effective as the injection 
of exogenous IL-1β.  
 
The observed beneficial effects of IL-1β on glucose 
homeostasis is in apparent contrast to the glucose 
lowering effects of IL-1 antagonism in patients with type 
2 diabetes54. The most obvious explanation is the 
difference between acute and chronic effects. Indeed, 
prolonged administration of IL-1β impaired glucose 
metabolism in mice. However, the positive effect of 
acute IL-1β on insulin secretion was maintained in 
animal models of diabetes despite chronically 
increased endogenous IL-1β levels. Similarly, fasting 
insulin levels of db/db mice and of diet induced obese 
mice were decreased by IL-1Ra treatment without 
changes in insulin sensitivity. A possible explanation to 
reconcile these findings is the concept of β-cell “rest”. 
Indeed, potassium channel openers, which decrease 
insulin secretion, improve insulin secretion in patients 
with type 2 diabetes79. Possibly, the benefit of IL-1 
antagonism in patients with type 2 diabetes is also due 
to β-cell rest and not only due to the postulated direct 
toxic effects of IL-1β. An alternative or additional 
	   39	  
explanation for the contrasting effects of acute versus 
chronic IL-1β exposure is based on the local production 
of IL-1β by islets in response to a metabolic stress21, 53. 
This islet-derived IL-1β may drive local production of 
chemokines followed by recruitment of detrimental 
immune cells. In contrast, systemic IL-1β will not create 
a chemokine gradient around the islets and subsequent 
insulitis will not occur.  
Based on our and previous studies, we propose that 
the physiological role of IL-1β in metabolism is to adapt 
glucose homeostasis to the needs of an innate immune 
response (Fig. 7). Indeed, IL-1β increases body 
temperature during infections4. This requires glucose 
uptake into muscle, which is directly promoted by IL-1β 
and indirectly via IL-1β stimulated insulin secretion. 
Furthermore, an infection often leads to insulin 
resistance in liver and adipose tissues, increasing the 
availability of glucose for immune cells. Importantly, our 
current work showed that IL-1β also supplies glucose 
to immune cells. Interestingly, insulin proved to be an 
enhancer of this IL-1β effect. In macrophages the role 
of insulin appeared to be most explicit in activated M1 
macrophages, which displayed higher levels of insulin 
receptor, allowing AKT to be phosphorylated, glycolytic 
activity to be increased and an overall pro-inflammatory 
pattern to be established. Finally, we showed that 
insulin is a previously unknown activator of the NLRP3 
inflammasome, inducing macrophage-derived IL-1β by 
enhanced glucose uptake through the glucose 
transporter GLUT1. Hence insulin, which is increased 
in early stages of type 2 diabetes, may sustain the 
inflammatory state and may therefore directly 
contribute to the chronic low grade inflammation 
associated with metabolic diseases. Conversely, IL-1β 
may stimulate insulin secretion to compensate for the 
increased demand of insulin during obesity. 
 
Altogether, our findings show that both IL-1β and 
insulin have potent effects on glucose homeostasis and 
on the immune system further supporting the emerging 
concept of immunometabolism. Understanding the 
physiological synergy between IL-1β and insulin on 
glucose disposal and macrophage activity may have 
important implications for the development and use of 
drugs modulating IL-1β and insulin actions in 
pathological conditions. 
 
METHODS 
 
Human pancreatic islets 
Human islets were isolated in the islet transplantation 
centres of Lille and Geneva from pancreata of cadaver 
organ donors in accordance with the local Institutional 
Ethical Committee. They were obtained via the “islet for 
research distribution program” through the European 
Consortium for Islet Transplantation, under the 
supervision of the Juvenile Diabetes Research 
Foundation (31-2008-416). Islets were cultured in 
CMRL-1066 medium containing 5 mmol/l glucose, 100 
units/ml penicillin, 100 µg/ml streptomycin, 2 mM 
Glutamax and 10 % FCS (Invitrogen) on extracellular 
matrix-coated 24-well plates (Novamed Ltd.) in humid 
environment containing 5 % CO2. Some islets were 
treated for 0.5-2h with 0.1, 0.5 and 1 ng/ml 
recombinant human IL-1β (R&D), 20 µM atropine 
(Sigma), or 10 µM carbachol (Sigma). 
 
Mouse pancreatic islets 
To isolate mouse islets, pancreata were perfused 
through the sphincter of oddi with a collagenase 
solution (Worthington) and digested in the same 
solution at 37°C, followed by sequential filtration 
through 500 µm and 70 µm cell strainers (BD). Islets 
were handpicked and cultured on extracellular matrix-
coated 24-well plates (Novamed Ltd.) in RPMI-1640 
(GIBCO) containing 11.1 mM glucose, 100 units/ml 
penicillin, 100 µg/ml streptomycin, 2 mM glutamax, 50 
µg/ml gentamycin, 10 µg/ml Fungison and 10 % FCS. 
Islets were either collected directly for RNA extraction 
or cultured for 36 hours on extracellular matrix-coated 
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24-well plates and treated for 24 hours with or without 
1ng/ml recombinant mouse IL-1β for subsequent RNA 
extraction as well as protein measurements in the 
supernatant or they were used for glucose-stimulated 
insulin secretion experiments.  
 
Animal experiments 
All animal experiments were performed in mice on a 
C57BL/6 background unless otherwise specified. WT 
mice were obtained from Charles River. For the diet 
induced obesity (DIO) experiments, 4 week old mice 
were fed a high fat diet (D12331, Research Diets; 
containing 58, 26 and 16 % calories from fat, 
carbohydrate and protein, respectively) for 20-25 
weeks. Leptin receptor deficient (db/db) mice were 
obtained from Jackson laboratories at the age of 4 
weeks, and housed until the age of 16 weeks. IRAK 4 
KO mice80 on a Balb/c background were kindly 
provided by Amgen. IL-1β KO mice were produced by 
gene targeting as previously described81. GLP1R GIPR 
KO mice were generated as described82. GFRα2-KO 
mice were obtained and genotyped as described 
earlier77. NLRP3 KO mice were generated as 
described56. RAG2 KO mice were bred in house. 
Crossing of Glut2 floxed mice83 with nestin-Cre 
transgenic mice was performed as previously 
described84 to generate mice deficient in Glut2 in nestin 
expressing cells.  
All animal experiments were conducted according to 
the Swiss Veterinary Law and Institutional Guidelines 
and were approved by the Swiss Authorities. All 
animals were housed in a temperature-controlled room 
with a 12 h light – 12 h dark cycle and had free access 
to food and water. All metabolic experiments using 
transgenic mice were performed using wild type 
littermates as controls. The mice were between 12 and 
29 weeks of age. Mice that did not gain weight in diet 
induced obesity experiments were excluded. All 
experiments were performed at least twice with weight-
matched mice and with at least 4 animals per group. 
For drug applications, each cage included mice 
receiving all treatments in order to avoid cage 
dependent differences. 
Glucose tolerance tests (GTTs) 
For glucose tolerance testing, mice were fasted for 6 
hours starting in the morning and injected ip or by 
gavage with 2 g glucose per kg body weight. LPS (1 
mg/kg body weight) was applied 3 hours, atropine 
(Sigma; 5 mg/kg body weight) or darifenacin (Santa 
Cruz; 5 mg/kg body weight) or exendin 9-39 (Bachem; 
1 µg/kg body weight) 36 minutes and, recombinant 
mouse IL-1β (0.1-1 µg/kg) 18 minutes before the start 
of the GTT. IL-1Ra (10 mg/kg body weight) was ip 
injected twice, 3 hours and 36 minutes prior to the 
glucose injection. Blood glucose was measured using a 
glucometer (Freestyle; Abbott Diabetes Care Inc.). For 
detection of active GLP-1, mice were ip injected with 25 
µg/kg sitagliptin (Sigma) 30 minutes prior to the GTT.  
 
ENDOC cells 
The human β-cell line (ENDOC) was kindly provided by 
R. Sharfmann and cultured and subjected to glucose-
stimulated insulin secretions as described earlier85. 
Human IL-1β (R&D) was added at the indicated 
concentrations for 30 minutes at 2.8 mM glucose 
concentration prior to the incubation with 16.7 mM 
glucose. 
 
Glucose-stimulated insulin secretion assay in islets 
For glucose-stimulated insulin secretion experiments, 
islets or ENDOC cells were cultured for 2 days and pre-
incubated for 30 minutes in modified Krebs-Ringer 
bicarbonate buffer (KRB; 115 mM NaCl, 4.7 mM KCl, 
2.6 mM CaCl2 2H2O, 1.2 mM KH2PO4, 1.2 mM MgSO4 
2H2O, 10 mM HEPES, 0.5 % bovine serum albumin, 
pH 7.4) containing 2.8 mM glucose. KRB was then 
replaced by KRB with 2.8 mM glucose and collected 
after 1 hour to determine the basal insulin release. IL-
1β was added at the indicated concentrations for the 
last 30 minutes of the 1-hour period of the basal insulin 
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release (priming). This was followed by 1 hour in KRB 
with 16.7 mM glucose to determine the stimulated 
insulin release. The stimulatory index was defined as 
the ratio of insulin secretion at 16.7 mM to 2.8 mM 
glucose/hour and expressed as percent of untreated 
control. 
 
Primary immune cell isolation and cultivation 
Mouse macrophages, splenocytes and T-cells were 
isolated from male C57BL/6 mice after euthanization in 
a CO2 chamber. To obtain circulating white blood cells 
(WBC), the hearth was punctured and the collected 
blood was incubated briefly with red blood cells lysis 
buffer (154mM NH4Cl, 10mM KHCO3, 0.1mM EDTA). 
To isolate macrophages, the peritoneum was infused 
with a PBS 1% FCS solution and the lavage was 
filtered through 70 µm cell strainer (BD). To isolate 
splenocytes, the spleen was minced and cells were 
passed through a 70 µm cell strainer and incubated 
with red blood cells lysis buffer. Cells were centrifuged 
at 350 x g for 5 minutes at 4oC. Macrophages and 
splenocytes were resuspended in culture media (same 
media used for mouse pancreatic islets). For T-cell 
isolation splenocytes were re-suspended according to 
the T-cell isolation kit protocol (Dynabeads untouched 
mouse T-cells, Invitrogen). Cells were cultured in 48 or 
96 well plates (TPP). Splenocytes and T-cells were 
kept in suspension for glucose uptake measurements. 
Macrophages were allowed to adhere for at least 4 
hours, naïve macrophages were used for glucose 
uptake assays or were polarized to M1 or M2 
phenotypes as follows: 2 hours (serum free) or 16 
hours treatment with LPS (100 ng/ml) + IFNγ (10 ng/ml) 
for M1 and IL-13 (10 ng/ml) + IL-4 (10 ng/ml) for M2 
polarization, followed by 2 or 24 hours, with or without 
1 µg/ml insulin in the presence or absence of fasentin 
(50 µM; Sigma). Supernatants were collected and 
stored at -80 oC and cells were harvested for RNA 
extraction (see RNA extraction and qPCR).  
 
RNA extraction and qPCR 
Total RNA was extracted using the Nucleo Spin RNA II 
Kit (Machery Nagel). cDNA was prepared with random 
hexamers (microsynth) and Superscript II (Invitrogen) 
according to the instructions of the supplier. RNA 
expression was determined with TaqMan assays and 
the real time PCR system 7500 (Applied Biosystems). 
The following TaqMan assays were used:  
Human: SLC18a3 (Vesicular acetylcholine 
gene,VAChT) Hs00268179_s1, 18s Hs99999901_s1. 
Mouse: GAPDH: Mm99999915_g1, TNFa: 
Mm00443258_m1, YM1, chitinase 3-like 3 (chi3l3): 
Mm00657889_m1, mannose receptor 1 (MRC1): 
Mm00485148_m1; IL-1Ra: Mm00446185_m1, SLC2a1 
(GLUT1): Mm00441480_m1. IL-1β: Mm0043228_m1, 
insulin receptor: Mm01211875_m1, KC (Cxcl1): 
Mm04207460_m1, CD40: Mm00441891_m1, 
Hexokinase 2 (HKII): Mm00443395_m1, IL-1α: 
Mm00439621_m1, NLRP3: Mm00840904_m1, IL-1 
Receptor type 1 (IL-1R1): Mm00434237_m1, IL-6: 
Mm0046190_m1, F4/80 (Emr1): Mm00802529_m1. 
Data were normalised with 18s for islets mRNA 
measurements or geometrical mean of GAPDH, 18s, 
actin for macrophage RNA and quantified using the 
comparative 2-ΔΔCT method. 
 
Protein measurement assays 
Insulin concentrations were determined using human 
insulin ultrasensitive ELISAs (Mercodia) or mouse/rat 
insulin kits (Mesoscale Discovery). Mouse IL-1β and 
active GLP-1 concentrations were assayed using the 
appropriate assays (Mesoscale Discovery). IL-1Ra was 
determined using ELISA assays (R&D).  
 
Glucose bio-distribution assay 
Male C57BL/6 mice were fasted for 3 hours in the 
morning, ip injected with IL-1β (1 µg/kg body weight) or 
saline and 18 minutes later with 3H labeled 2-deoxy 
glucose (10 µCi per mouse, Perkin Elmer). After 30 
minutes mice were sacrificed, liver, quadriceps muscle, 
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visceral adipose tissue, and spleen were weighed, 
washed immediately in ice cold PBS and incubated 
with lysis buffer (10% glycerol, 5% 2-mercaptoethanol, 
2.3% SDS, 62.5mM Tris pH6.8, 6M urea) followed by 
sonication. WBC were isolated as described above, 
washed twice with ice cold PBS, counted and lysed 
with 0.1% SDS. Triplicate samples were then 
measured in a beta counter. Data are presented as 
percentage beta counts per minute per mg tissue, in 
organs or beta counts per cell in WBC.  
 
In vitro glucose uptake assay 
For in vitro treatment, macrophage, and T-cells were 
incubated for 2 hours (Macrophages) or 40 minutes (T-
cells) with 1 mM glucose KRB (as described in GSIS 
section) with or without the indicated treatment. To 
determine glucose uptake, macrophages, T-cells, and 
splenocytes were then incubated for 30 minutes with 
0.4 nCi 3H labeled 2-deoxy glucose (Perkin Elmer), 
washed twice with ice cold PBS, lysed with 0.1 % SDS 
and transferred into scintillation fluid. 3H labeled 2-
deoxy glucose uptake was measured in a beta counter. 
 
Glucose clamp studies 
Glucose clamp studies were performed in freely 
moving mice as previously described86. Steady state 
glucose infusion rate was calculated once glucose 
infusion reached a constant rate with blood glucose 
levels at 5 mmol/l (70-80 minutes after the start of 
insulin infusion). Thereafter, blood glucose 
concentration was kept constant at 5 mmol/l for 15-20 
minutes and glucose infusion rate was calculated. 
Glucose disposal rate, endogenous glucose production 
and insulin‐stimulated glucose disposal rate were 
calculated as described87. 
 
Implantation of osmotic pumps releasing IL-1β 
C57BL/6, male mice, were subcutaneously implanted 
with osmotic mini pumps (Alzet 2006) releasing either 
recombinant mouse IL-1β (R&D; 0.1 µg/kg/day) or 
saline for 31 days. Surgery was done in an SPF 
environment; animals were anaesthetised with Ketalar 
(65 mg/kg) and Xylasol (13 mg/kg) by ip injections. 
After falling asleep eye creme (Floxal) was applied to 
avoid dry eyes and the neck was shaved. As 
preparation to the pump implantation, an air pocket 
was created under the skin. The sterile pumps were 
inserted in the pocket and the wound was closed with 
two wound clips. Mice were single caged and kept 
under a warming lamp. After the first signs of waking, 
painkiller (Temgesic; 0.05 mg/kg) was injected 
subcutaneously. After 24 hours and eventually 48 
hours (if the mice were scratching themselves), another 
shot of painkiller was given. Healing of the wound and 
the health state of every mouse was observed and 
recorded on a score sheet every day for one week. All 
animals were housed single caged. On days 17 and 31 
mice underwent glucose tolerance testing. 
 
In vivo daily injections of IL-1β  
Low dose: male C57BL/6 mice were injected daily at 
16:00 with the same dose used for acute IL-1β (1 µg 
per kg body weight) or saline for either 6 or 13 days. 
Intermediate dose: male C57BL/6 mice were injected 
daily at 8:00 with saline or 10 µg/kg body weight for 5 
days or once on the day of GTT. High dose: male 
C57BL/6 mice were injected daily at 16:00 with saline 
or 35 µg/kg IL-1β for 3 days. 
 
Western blotting. 
We separated proteins (8-12 µg) in 4-12 % NuPAGE 
gels (Invitrogen), blotted them onto nitrocellulose 
membranes (Bio-Rad) and incubated them with 
antibodies against total AKT (pan AKT; #4691), pAKT 
(s473; #9271) (Cell Signaling). Blots were analyzed 
using image lab 4.1 software (Bio-Rad).  
 
Cellular respiration and extracellular acidification 
measurements. 
An XF96e Extracellular Flux analyser (Seahorse 
Biosciences) was used to determine the bioenergetic 
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profile of macrophages. Peritoneal cells were plated at 
a density of 300’000 cells per well in XF96 plate, 
incubated for 4 hours, and washed vigorously before 
being stimulated with LPS (100 ng/ml) + IFNγ (10 
ng/ml) or IL-4\IL-13 (10 ng/ml) overnight. The next day 
insulin was added to the media (1 µg/ml end 
concentration) for 2 hours. Prior to the assay, cells 
were incubated in unbuffered RPMI (Seahorse 
Biosciences) containing 11.1mM glucose for 1 hour. 
Then oxygen consumption rate and extracellular 
acidification rate were assessed during 2 minutes. Four 
basal measurements were followed by 5 
measurements upon injection of the following agents: 
Glucose (26.8 mM), oligomycin (1 uM), carbonilcyanide 
p-triflouromethoxyphenylhydrazone (FCCP) (2 µM) and 
rotenone (1 uM). Oligomycin, FCCP and rotenone were 
purchased from Sigma. 
 
Macrophage ablation 
Clodronate or PBS liposomes 
(ClodronateLiposomes.org) were injected on two 
consecutive days, the first day ip and the second day 
intravenously (50ul per 10 grams bodyweight each 
injection). Mice were sacrificed at the end of the 
procedure and in order to control macrophage 
depletion, splenocytes and peritoneal cells were 
isolated as described above and analysed by FACS 
analysis as described below. Macrophages were 
defined as CD11b+ F4/80+ double positive cells. 
Flow cytometry 
To obtain single cells, islets were dispersed with trypsin 
(Invitrogen) for 6 minutes at 37°C, washed with PBS, 
pelleted at 300 x g, 5 minutes, 4oC and re suspended 
in FACS buffer (PBS with 0.5% BSA and 2 mM EDTA). 
After 15 minutes incubation with an Fc blocker (Anti-
mouse CD16/CD32; eBioscience 14-0161) splenocytes 
or single islet cells were stained with the appropriate 
antibody for 30 minutes at 4°C in the dark. To control 
the effect of the clodronate depletion splenocytes from 
RAG2 KO mice were stained with anti F4/80-PE (Clone 
BM8; 12-4801), anti CD11b-eFluor660 (Clone M1/70; 
50-0112) and CD45-FITC (Clone 30-F11; 11-0451). 
Single islet cells were stained with CD45-PE-cy7 
(Clone 30-F11; 25-0451) for immune cells (all 
antibodies were purchased from eBioscience). Stained 
cells were washed twice with FACS buffer prior to 
FACS. Splenocytes from chlodronate treated mice 
were analyzed on an Accuri C6 flow cytometer (BD 
Bioscience). Dispersed islet cells were analyzed and 
sorted on a FACS ARIA III cell sorter (BD Biosciences) 
using FACS Diva software (BD Biosciences). All 
samples were stained with appropriate isotype control 
antibodies; viability staining was done using 7-AAD 
(Sigma) or DAPI (for the sort). Data were analysed 
using Flow Jo 9.4 software (Tree Star).  
 
Immunofluorescence staining 
Pancreata were fixed overnight in 4% 
paraformaldehyde at 4oC, followed by paraffin 
embedding. Sections were deparaffinized, re-hydrated, 
and incubated 1 hour at room temperature with guinea 
pig anti-insulin antibody (Dako; A0564), followed by 
detection with a fluorescein-conjugated donkey anti-
guinea pig antibody (Dako). Subsequently, the sections 
were labeled for IL-1R1 with goat anti IL-1-R1 antibody 
(R&D; AF771), followed by detection with a fluorescein-
conjugated donkey anti-goat antibody (Invitrogen).  
 
Statistics 
Appropriate statistical tests were performed where 
required. Two-sided unpaired Student's t-tests were 
performed for all statistical analyses unless otherwise 
specified using GraphPad Prism 5 (GraphPad 
Software). Data are expressed as means ± s.e.m. and 
statistical significance is denoted as *P < 0.05, **P < 
0.01, ***P < 0.001 and, ****P < 0.0001. n numbers 
indicate biological replicates for in vitro experiments or 
number of mice for in vivo experiments.  
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Figure 1. IL-1β acutely is a potent insulin secretagogue and improves glucose disposal in normal, 
obese and diabetic mice. (a) Plasma concentrations of IL-1β following an intraperitoneal (ip) injection of 
IL-1β into wild type (WT) mice. Mice were injected with saline (n=4) or 0.25 (n=6), 0.5 (n=5), and 1 (n=9) 
µg/kg IL-1β at time 0. (b) Glucose and (c) insulin levels during an ip glucose tolerance test (ipGTT) in mice 
18 minutes after a single injection with saline (n=5) or 0.25 (n=7), 0.5 (n=8), 1 (n=6) µg/kg IL-1β. (d) Insulin 
tolerance test (ITT) 18 minutes after an injection of 1 µg/kg IL-1β. Hyper-insulinemic euglycemic clamp in 
mice pre-treated with 1 µg/kg IL-1β (n=5): (e) glucose infusion rate, (f) hepatic glucose production. Glucose 
(g, i, k) and insulin (h, j, l) levels during an ipGTT with diet induce obese (DIO) (g, h), db/db (i, j) and IRAK4 
knockout (KO) (k, l) mice, pre-treated with 1 µg/kg IL-1β (n=12, 12 and 6 per group, respectively). (m) 
Glucose and (n) insulin levels in mice injected with 1 µg/kg IL-1β or saline alone or in combination with 
glucose (n=8). (o) Delta AUC insulin of IL-1β-saline and glucose-saline alone or in combination. (p) Double 
immunostaining of IL-1 receptor type 1 (IL-1R1) and insulin in pancreatic tissue sections of WT and IL-1R1 
KO mice. (q) IL-1R1 mRNA expression in FACS sorted islet cells (n=6). (r-t) Insulin concentrations in 
cultured media of islets isolated from mice (r; left to right: n=9,13,9,12; 3 experiment) and humans (s; left to 
right: n=44,9,34,15; 8 experiment) and of ENDOC cells (t; n=9; 3 experiment) pre-incubated with IL-1β 
followed by incubation at low (2.8 mM) and high (16.7 mM) glucose. *P < 0.05, **P < 0.01, ****P < 0.0001. 
Statistical significance (P) was determined by Student's t test. All error bars denote s.e.m. 
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Figure 2. Endogenous IL-1β plays a role in insulin secretion. (a-c) Plasma concentrations of IL-1β (a) blood 
glucose (b) and insulin (c) after an intraperitoneal (ip) injection of 1 mg/kg LPS in mice (n=8). (d) Insulin levels of wild 
type (WT) and IL-1β knockout (KO) mice injected with LPS (n=7; ANOVA). (e) Glucose and (f) insulin levels during 
an ip glucose tolerance test (ipGTT) in normal or diet induced obese (DIO) mice pre-injected with LPS 3 hours 
before (n=5; significance level indicating differences between saline and LPS treated WT or DIO mice). (g) 
Circulating insulin levels during an ipGTT from mice pre-injected with LPS in combination with or without IL-1Ra 
(n=5; significance level indicating differences between LPS and LPS+IL-1Ra treated mice). (h) Circulating insulin 
levels during an ipGTT from WT or NLRP3 KO mice pre-injected with LPS (n=8). (i) Basal insulin levels following 
acute injections of 10 mg/kg IL-1Ra in DIO mice. (j) Hyper-insulinemic euglycemic clamp in DIO mice pre-injected 
with saline or IL-1Ra (n=4,5 respectively). (k) Basal insulin levels after acute saline or IL-1Ra injections in db/db mice 
(n=6,5 respectively). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Statistical significance (P) was determined 
by Student's t test and in (d) by ANOVA. All error bars denote s.e.m.  
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Figure 3. Long term IL-1β administration impairs glucose metabolism. Blood glucose (a, c, e, g, i) and 
insulin (b, d, f, h, j) levels during an intraperitoneal glucose tolerance test (ipGTT) in (a, b) mice following a 
single (n=6), or daily for 6 days injection of saline or 10 µg/kg IL-1β (n=5,7 respectively), or (c,d) after daily 
injections for 3 days with 35 µg/kg IL-1β (n=5), or after (e, f) 17 and (g, h) 31 days after implantation of pumps 
delivering IL-1β (n=6), or (I, j) following daily injections of 1 µg/kg IL-1β for 13 days (n=10). (k) mRNA 
expression of islets isolated from mice injected daily with saline or 1 µg/kg IL-1β for 14 days (n=7,9 
respectively). *P < 0.05, **P < 0.01. Statistical significance (P) was determined by Student's t test. All error 
bars denote s.e.m.  
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Figure 4.  IL-1β induced insulin secretion is partly mediated by neuronal stimulation and is independent of the 
incretin system. (a) Blood glucose (n=8) and (b) insulin (n=16) levels during an oral glucose tolerance test (oGTT) in 
mice 18 minutes after a single injection of 1 µg/kg IL-1β. (c) Blood glucose (n=7) (d) insulin (n=7) and (e) active GLP-1 
(saline; n=13, IL-1β; n=14) during an intraperitoneal glucose tolerance test (ipGTT) in mice 18 minutes after a single 
injection of 1 µg/kg IL-1β with or without exendin 9-39. (f) Blood glucose (g) and insulin during an ipGTT in GIP and 
GLP-1 receptor double knockout (KO; n=7) or wild type (WT; n=8) littermate control mice 18 minutes after a single 
injection of saline or 1 µg/kg IL-1β. (h, k) Blood glucose and (i, j, l) insulin from mice after a single injection of 1 µg/kg 
IL-1β with or without 5 mg/kg atropine (n=7) or 5 mg/kg darifenacin (n=12). (m-n) Insulin concentrations of culture 
media supernatants of islets isolated from human (m; n=34) or mouse (n; n=24) pre-incubated with 0.5 ng/ml IL-1β 
with or without 20 µM atropine followed by incubation at 2.8 mM and 16.7 mM glucose. (o-r) Vesicular acetylcholine 
transporter (vAChT) mRNA expression in: human (o; n=33) and mouse (p; n=16) islets treated for 24h with IL-1β 
(1ng/ml) and ex vivo in islets isolated from mice treated for 14 days with saline or IL-1β (q; n=6,9 respectively), or from 
WT mice and diet induced obese (DIO) mice (r; n=29,28 mice, respectively). (s) Blood glucose and (t) insulin levels 
during an ipGTT in DIO mice 18 minutes after a single injection of saline 1 µg/kg IL-1β with or without 5 mg/kg atropine 
(n=7,8,7,7, respectively). (u) Blood glucose and (v) insulin levels during an ipGTT in WT and GFRα2 KO littermate 
mice 18 minutes after a single injection of 1 µg/kg IL-1β (n=5). *P < 0.05, **P < 0.01. Statistical significance (P) was 
determined by Student's t test. All error bars denote s.e.m.  
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Figure 5. IL-1β promotes insulin independent glucose uptake in muscle, fat and immune cells but not in the 
liver. (a-g) Mice were injected intraperitoneally (ip) with 1 µg/kg IL-1β and 10 µCi 3H labeled 2-deoxy glucose 18 
minutes prior to sacrifice and assessment of circulating insulin (a; n=4); glucose uptake in muscle (b; n=8), liver (c; 
n=8), visceral adipose tissue (VAT; d; n=8), adipocytes isolated from epidydymal fat pads (e; n=4), spleen (f; n=4), 
and circulating white blood cells (WBC; g; n=8). (h-l; n=5) Mice were injected once a day for 3 days with 35 µg/kg IL-
1β: number of peritoneal cells (h) and of lymph node cells (i), spleen weight (j), and glucose uptake in macrophages 
(k) and lymph node cells (l). (m-o) In vitro glucose uptake in: T cells incubated with IL-1β for 30 minutes (m; n=32, 3 
experiments) and, macrophages incubated with IL-1β for 2 hours (n; n=15, 11, respectively, 3 experiments) and, in 
macrophages incubated with saline or IL-1Ra for 3 hours (o; n=14,9 respectively; 3 experiments). (p) Blood glucose 
levels during an oGTT 18 minutes after a single injection of saline or 1 µg/kg IL-1β in RAG2 deficient (n=6) and 
littermate heterozygous (Hets; n=7) mice. (q,r) macrophage (CD11b+, F4/80+ double positive cells) ablation in RAG2 
ko mice: (q) Representative flow cytometer analysis of macrophage depletion in spleen and peritoneal cells from 
RAG2 deficient mice, using 2 injections of 10 ml/kg clodronate or PBS liposomes, and (r) blood glucose levels during 
an oGTT after treatment with 1 µg/kg IL-1β (PBS; n=13, clodronate; n=9). *P < 0.05, **P < 0.01,. Statistical 
significance (P) was determined by Student's t test. All error bars denote s.e.m.  
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Figure 6. Insulin regulates macrophage metabolism and stimulates IL-1β via the NLRP3 inflammasome. (a) 
Glucose uptake in naïve macrophages (control; n=21; 3 experiments) or incubated for 3 hours with 1 µg/ml insulin 
alone (n=28; 3 experiments) or in combination with 1 ng/ml IL-1β (n=15; 3 experiments). (b) Insulin receptor mRNA 
expression in naïve (M0; n=11; 3 experiments), pro-inflammatory M1 (LPS+IFNγ; n=11; 3 experiments) and alternative 
M2 (IL-4+IL-13; n=12; 3 experiments) polarized macrophages (ANOVA). (c) Insulin induced (s473) phospho-AKT in 
polarized macrophages, data presented as ratio of insulin to non-insulin treated cells after normalization to total AKT 
(n=3 experiments) and a representative Western blot. Seahorse measurements and AUC of (d) extracellular 
acidification rate (ECAR; mpH/min) and of (e) oxygen consumption rate (OCR; pmol/min) from polarized macrophages 
incubated for 2 hours in the presence or absence of insulin. (n=12,15 respectively; 3 experiments). (f) Gene expression 
from naïve and polarized macrophages with or without 1 µg/ml insulin: data are expressed as percentage change from 
untreated controls (n=12, 3 experiments). (g) IL-1β and (h) IL-1Ra protein secretion from polarized macrophages with 
or without 1 µg/ml insulin (n=12). (i) 2 hour IL-1β protein secretion from M1 macrophages with or without 50 µM 
fasentin and 1 µg/ml insulin: data are presented as fold stimulation from non-insulin treated (n=14, 3 experiments). (j) 2 
hour IL-1β protein secretion from polarized macrophages isolated from wild type (WT) or NLRP3 knockout (KO) mice 
with or without 1 µg/ml insulin and (k) corresponding gene expression (n=9, 3 experiments). *P < 0.05, **P < 0.01, ***P 
< 0.001. Statistical significance (P) was determined by Student's t test and in (b) by ANOVA. All error bars denote 
s.e.m.  
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Figure 7 Proposed model describing the physiological role of IL-1β and insulin in the regulation of 
glucose metabolism during acute activation of the innate immune system.  Bacterial cell wall products 
such as lipopolysaccharide (LPS) induce IL-1β secretion from macrophages. IL-1β then stimulates insulin 
secretion directly from pancreatic β-cells via the highly expressed IL-1 receptor 1 (IL-1R1) and the IL-1 receptor-
associated kinase-4 (IRAK-4), and indirectly via parasympathetic nerves. The secreted insulin binds to its 
receptor (INSR), which is up-regulated in activated M1 macrophages, leading to enhanced AKT phosphorylation, 
glycolytic activity and cytokine expression such as TNF, KC and IL-1α. Insulin signaling also enhances 
macrophage-derived IL-1β by increasing glucose uptake through the glucose transporter GLUT1 and activation 
of the NLRP3 inflammasome. Increased levels of IL-1β alone and in combination with insulin enhance glucose 
uptake into muscle, adipose tissue, and in macrophages as well as other immune cells, and consequently 
decrease glycaemia. 
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Supplementary Figure Plasma concentrations of (a) IL-1β and (b) insulin 15 minutes after an 
intraperitoneal (ip) injection of saline or 0.1 or 1 µg/kg IL-1β. (c, e) Glucose infusion rate and (d, f) percent 
inhibition of hepatic glucose production by insulin in (c, d) wild type (WT) mice primed with 1 µg /kg IL-1β, 
and in (e, f) diet induced obese (DIO) mice injected with 10 mg/kg IL-1Ra. (g) Blood glucose during an 
ipGTT in nestin-cre-glut2 KO and littermate controls mice primed with saline 1 µg/kg IL-1β, 18 minutes 
before glucose injections (n=4,5 respectively). (h) IL-1β, CD40 (pro-inflammatory, M1 marker) and 
chitinase-like 3 (Chi3l3; alternative, M2 marker) gene expression from naïve (M0), M1 and, M2 polarized 
macrophages (n=12). 	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3 Unpublished results 
3.1 Glucose did not induce IL-1β in an oGTT 
Since LPS derived or exogenously administered IL-1β induced insulin secretion in 
vivo (Fig. 1, Fig. 2), the involvment of IL-1β in insulin secretion after oral ingestion 
of glucose was evaluated. Since glucose is the main fuel for IL-1β producing 
macrophages and FFAs activates NLRP3 inflammasome, WT mice received 
glucose or corn oil orally; blood was collected for evaluation of circulating IL-1β 
levels. Control mice received water. As seen in Fig. 4 (unpublished), no significant 
differences between the groups were detected.  
Figure 4. Circulating IL-1β levels post glucose ingestion. (a) IL-1β levels percentage in the 
circulation or (b) percentage change from baseline, from mice after oral administration (5 times 
bodyweight) of water, glucose, or corn oil (8 calories/kg, equivalent to 2gr/kg glucose; n=14,16,10, 
respectively,). 
3.2 Potential role of IL-1β in the inhibition of GLP-1 secretion. 
A disconnection between insulin levels and blood glucose levels in IL-1β injected 
mice is presented in the above manuscript. A further example for this 
disconnection is shown in Fig. 4a,b. Oral administration of glucose resulted in 
improved glycaemia in mice treated with IL-1β compared to saline treated mice, 
however, in contrast to intraperitoneal glucose administration, no difference in 
circulating insulin levels were detected. Since the major cause for the difference 
between oral and intraperitoneal administration of glucose is the incretin effect, 
the effect of IL-1β on incretin secretion was evaluated. Mice were injected with 
sitagliptin (as described in methods) followed by injection of 1ug/kg IL-1β, and 18 
minutes later an oral glucose tolerance test was performed. Interestingly, IL-1β 
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treated mice had lower levels of circulating active GLP-1 than the control group 
(Saline; unpublished, Fig. 5). 
Figure 5. Lowered circulating active GLP-1 in mice injected with IL-1β. Data from oral 
glucose tolerance test (oGTT) performed in wild type (WT) mice 18 minutes after injection of 
saline or 1 μg/kg IL-1β (n=13,12, respectively). (a) Blood glucose levels. (b) Circulating GLP-1. (c) 
Circulating insulin. 
3.3 Diet induce obese mice have higher IL-1R1 expression 
To further investigate the physiological role of IL-1β in insulin assessment of IL-
1R1 expression in DIO compared to WT mice was performed (unpublished, Fig. 
6). Immunohistochemistry of pancreata of DIO mice displayed  2.5 fold more IL-
1R1 expressing β-cells than WT mice.  
Figure 6. IL-1R1 expression in islets from WT and DIO mice. (a) Analysis of β-cells expressing 
IL-1R1, data are presented as ratio between IL-1R1 positive and insulin positive cells (n=24, 6 
islets from 4 mice per group). (b) Representative insulin (green), IL-1R1 (red) staining of 
pancreatic islet (surrounded in white) section (X40 magnification). For IL-1R1 staining control see 
Fig. 1 in submitted manuscript. All pictures were acquired using the same settings. 
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4 Discussion 
4.1 IL-1β is a potent insulin secretagogue in normal, obese and, 
diabetic mice 
The deleterious effects of IL-1β on islet function and survival are well described 
and IL-1β was frequently used as a tool to provoke β-cell demise49, 71, 72. 
Surprisingly, at low concentrations or upon short exposure, IL-1β modestly 
stimulates insulin secretion in isolated islets indicating that IL-1β may not only be 
detrimental for β-cells but may have more complex biological functions4, 52. The 
insulin secretagogue effect of IL-1β is potentiated by glucose and conserved in 
human and mouse models. A possible physiological role of IL-1β in islets is also 
suggested by the previous observation of high levels of IL-1 receptor mRNA 
expression in whole islets20 and in the present study by its prominent expression 
in β-cells. Interestingly, not all β-cells were positive for IL-1R1 (Fig. 1). This 
means that IL-1R1 is a novel marker for a β-cell sub population. Of note, IL-1R1 
expression in DIO mice was higher compared to WT mice (unpublished data, Fig. 
3), further pointing to a physiological role of IL-1β in insulin secretion and 
adaptation to the increased demand of insulin in insulin resistance. Indeed, acute 
IL-1Ra injections in DIO mice attenuated basal insulin secretion. Injections of IL-
1β shortly prior to a glucose bolus massively improved glucose disposal in WT, 
DIO and, db/db mice supporting previous findings with pharmacological doses of 
IL-1β73, 78. Of note, these mouse models of insulin resistance secrete large 
amounts of insulin to compensate for the resistance and hardly develop β-cell 
failure. The present study shows that as long as functioning β-cells are present, 
acutely administrated IL-1β will result in increased insulin secretion. This occurs 
via direct action on islet β cells and via activation of neurons involved in the 
release of insulin. Furthermore,  the glucose lowering effect of IL-1β is also due to 
direct IL-1β-mediated glucose uptake into various tissues as will be further 
discussed.  
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4.2 Endogenous IL-1β plays a role in insulin secretion 
The physiological relevance of the present findings was demonstrated by LPS-
induced endogenous IL-1β secretion which was equally effective as the injections 
of exogenous IL-1β. Furthermore, a role of endogenous IL-1β in the stimulation of 
insulin secretion was also demonstrated  by blocking IL-1 signaling with IL-1Ra in 
DIO mice.  
The bacterial wall component LPS is an inducer of the innate immune system by 
promoting inflammation via activation of the toll like receptor and by the 
subsequent secretion of various cytokines including IL-1β. Although LPS injected 
mice reached a peak concentration in the circulation of only 5 pg/ml IL-1β, insulin 
was strongly induced, but not in the presence of IL-1Ra or in NLRP3 deficient 
mice, indicating the potency of LPS derived IL-1β as an insulin secretagogue. 
However, it is likely that the levels of IL-1β in the circulation do not reflect its 
concentration in target cells and organs. 
Numerous studies link high energy and fat rich diet with activation of the immune 
system and endotoxemia53, 88, a state where LPS levels are elevated in the 
circulating. In addition, recent reports provide evidence that free fatty acids are 
activators of TLRs and inducers of the NLRP3 inflammasome28. The present 
study demonstrates the importance of elevated IL-1β levels after LPS 
administration for insulin secretion. Elevation of FFAs after a high fat meal as well 
as elevation of LPS levels, that can occur due to intestine permeability allowing 
gut microbiota to penetrate into the circulation, may lead to IL-1β induced insulin 
secretion. In turn, IL-1β reduces glycaemia and activates the immune system to 
fight intruding microbiota. However as shown in unpublished results (fig. 1), 
circulating IL-1β levels were not elevated after high fat or high glucose ingestion.  
This may be the case for three reasons, first, circulating IL-1β levels do not reflect 
its local production, second, the settings of the experiment does not reflect 
physiological food intake and a mixed meal rather than glucose or oil gavage may 
be the proper way to perform this assay. Third, IL-1β is an extremely potent 
cytokine acting at levels bellow the detection of commercially available assays. 
Hence in order to evaluate the role of endogenously produced IL-1β we blocked 
its activity with IL1Ra. Indeed, DIO and db/db mice acutely injected with IL-1Ra 
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had basally lower circulating insulin levels which were not due to altered insulin 
sensitivity as demonstrated in clamp studies.  Altogether, this provides evidence 
that IL-1β has a physiological role in insulin secretion and the adaptation to the 
increased demand of insulin in states of obesity and insulin resistance. 
 
4.3 Improvement of glycaemia by IL-1β is partly mediated via 
neuronal stimulation of insulin secretion and is independent of 
the incretin system. 
In this study, the effect of IL-1β was much stronger when applied together with a 
glucose bolus. This suggests that IL-1β potentiates glucose stimulated insulin 
secretion resembling the effect of G-coupled receptors as described above 
(Introduction; 1.3.1). Hence, the involvement of major G coupled receptor 
agonists involved in insulin secretion (incretins and acetylcholine) were 
investigated. According to the results presented in Fig. 4 c,d,f,g, incretins do not 
contribute to IL-1β stimulated insulin secretion. Both WT mice treated with GLP-1 
receptor antagonist (exendin 9-39) and incretin receptor ko mice responded as 
their untreated or littermate controls, respectively. In addition, GLP-1 levels were 
not different in IL-1β injected mice compared to saline injected controls. However 
upon oral glucose administration, the physiological way of glucose ingestion, IL-
1β treated mice had lower GLP-1 levels in the circulation compared to saline 
injected controls while insulin levels were equal (unpublished data Fig 2). A 
possible explanation for this observation is that upon oral ingestion IL-1β inhibits 
the incretin secretion but at the same time directly induces insulin. However, once 
applied intraperitoneally, glucose does not stimulate the secretion of incretins 
therefore the effect of IL-1β on insulin secretion is detectable. Interestingly, even 
though circulating insulin levels were similar and GLP-1 levels were lower, IL-1β 
treated mice had improved glucose tolerance pointing on a role of IL-1β in 
glucose clearance as discussed below. 
The present study results indicate that besides its direct secretagogue effect in 
islets, IL-1β mediates insulin secretion via neuronal stimulation. Atropine partially 
blocked the effect of IL-1β in WT and DIO mice demonstrating the contribution of 
acetylcholine acting via muscarinic receptor in IL-1β mediated insulin secretion 
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(Fig. 4 h-j, s-v). In addition, darifenacin, an M3 muscarinic receptor blocker, that 
does not cross the blood brain barrier, failed to block the effect of IL-1β indicating 
that the central nervous system (CNS) participates in the observed effect.  
The role of IL-1β in the CNS is well described89 and the role of the CNS in 
immunity is emerging90. One may speculate that IL-1β signals to the brain that an 
inflammatory process is taking place, thus temperature homeostasis is disturbed 
and this in turn initiates shivering in order to increase the body temperature which 
in turn increases the glucose demand. At the same time, nerves stimulate insulin 
that enhances glucose uptake to the deprived compartments. As shown before 
nerves may signal to the immune system further activating or attenuating 
inflammatory processes91, 92 as a positive or a negative feedback. 
Moreover, in vitro, IL-1β stimulated insulin secretion was blocked by atropine 
confirming the observation of the presence of ACh in human islets76. This 
inhibitory effect of atropine appeared only in human islets. Interestingly, RNA 
levels of vesicular ACh transporter (vAChT) were elevated upon treatment with IL-
1β in both murine and human islets or when isolated from DIO mice. These 
findings indicate a possible role of chronically elevated IL-1β in the induction of 
ACh as a paracrine inducer of insulin. Of note, it has been previously 
demonstrated that treatment with cholinergic agonist normalized glucose 
tolerance. Further,  insulin secretion is more pronounced in DIO mice than in WT 
mice93. This may be partially attributed to IL-1β as it also increased the levels of 
M3 muscarinic receptor in mouse islets (preliminary- not shown).  
   
4.4 IL-1β promotes insulin independent glucose uptake in muscle, 
fat and immune cells but not in the liver 
In the present study we observed several times that the link between insulin and 
reduced glycaemia was disconnected. In some experimental settings blood 
glucose levels were different between treatments while insulin levels were 
unchanged (Fig. 3, Fig 4 a,b). Since IL-1β had no effect on insulin sensitivity (Fig. 
1 d-f, sup Fig. 1), the direct effect of IL-1β on glucose disposal was investigated. 
Three approaches were used to adress this. In the first approach (Fig. 5 a-g), IL-
1β was injected in the absence of a glucose bolus. Glucose uptake was evaluated 
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using trace amounts of radiolabeled, non-metabolizable glucose and therefore 
insulin levels were not changed. Various tissues had increased glucose uptake 
upon IL-1β treatment . This suggests that the observed increase in muscle, 
adipose tissue, adipocytes, spleen and, circulating white blood cells (WBC) is due 
to a direct effect of IL-1β on glucose uptake. Thus, the role of IL-1β as a pyrogen 
during infections94 may be attributed to a direct increase in glucose uptake (and 
indirectly via IL-1β stimulated insulin secretion) in muscle. Additionally, this 
increase in glucose uptake in various tissues may contributes to insulin resistance 
as seen previously in adipocytes26. In the second approach (Fig 5 h-o), IL-1β was 
administered or blocked at ambient glucose levels in vivo or in vitro, and the focus 
was on immune cells glucose uptake. IL-1β increased immune cell glucose 
consumption. This was associated with an elevation of the glycolytic capacity 
which may promote the activation of the immune system and of  inflammatory 
processed. Moreover, endogenously produced IL-1β acts in an autocrine manner 
elevating glucose uptake (Fig. 5 o). In the third approach (Fig 5 q,r), the 
contribution of macrophages to changes in circulating glucose levels was 
evaluated. IL-1β was injected into macrophage ablated and T and B cell deficient 
mice (RAG2 KO) during an oral glucose bolus. In these mice, the glucose 
lowering effect of IL-1β was dampened, demonstrating the potency of immune 
cells, mainly macrophages, to consume glucose and contribute to glucose 
disposal. 
Furthermore and in line with these results, an infection often leads to insulin 
resistance in liver and adipose tissues, increasing the availability of glucose for 
immune cells.  
Altogether, these results provide a firm proof that the immune system not only 
influences whole body glucose metabolism via changes in insulin sensitivity (as it 
is well established28, 47, 48) but also via glucose consumption and thereby 
contributes to changes in glycaemia. The physiological role of IL-1β in 
metabolism is to adapt glucose homeostasis to the needs of an innate immune 
response. 
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4.5 Insulin regulates macrophage metabolism and stimulates IL-1β 
via the NLRP3 inflammasome 
The current work shows two main functions of IL-1β. First, IL-1β is a potent 
insulin secretagogue and second, IL-1β directly enhances the glucose supply into 
immune cells. Interestingly, insulin proved to be an enhancer of this IL-1β effect. 
In macrophages the role of insulin appeared to be most explicit in activated M1 
macrophages, which express increased insulin receptor density, leading to 
enhanced AKT phosphorylation, glycolytic activity and cytokine expression such 
as TNF, KC and IL-1α. Finally, insulin is a previously unknown activator of the 
NLRP3 inflammasome, inducing macrophage-derived IL-1β by enhanced glucose 
uptake through the glucose transporter GLUT1. Hence insulin, which is increased 
in early stages of type 2 diabetes, may sustain the inflammatory state and may 
therefore directly contribute to the chronic low-grade inflammation associated with 
metabolic diseases. Conversely, IL-1β may stimulate insulin secretion to 
compensate for the increased demand of insulin during obesity, and this is via its 
up-regulated receptors (IL-1R1) on a β-cell subpopulation. 
4.6 The logic behind IL-1 receptor antagonism as treatment for T2D 
The observed beneficial effect of IL-1β on glucose homeostasis is in apparent 
contrast to the glucose lowering effects of IL-1 antagonism in patients with type 2 
diabetes54. The most obvious explanation is the difference between acute and 
chronic effects. Indeed, prolonged administration of IL-1β impaired glucose 
metabolism in mice (Fig. 3). However, the positive effect of acute IL-1β on insulin 
secretion was maintained in animal models of diabetes despite chronically 
increased endogenous IL-1β levels. Similarly, fasting insulin levels of db/db mice 
and of diet induced obese mice were decreased by IL-1Ra treatment without 
changes in insulin sensitivity. A possible explanation to reconcile these findings is 
the concept of β-cell “rest”. Indeed, potassium channel openers, which decrease 
insulin secretion, improve insulin secretion in patients with type 2 diabetes79. 
Possibly, the benefit of IL-1 antagonism in patients with type 2 diabetes is also 
due to β-cell rest and not only due to the postulated direct toxic effects of IL-1β. 
An alternative or additional explanation for the contrasting effects of acute versus 
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chronic IL-1β exposure is based on the local production of IL-1β by islets in 
response to a metabolic stress21, 53. This islet-derived IL-1β may drive local 
production of chemokines followed by recruitment of detrimental immune cells. In 
contrast, systemic IL-1β will not create a chemokine gradient around the islets 
and subsequent insulitis will not occur. 
 
5 Conclusion and outlook 
Overall, the findings from this work show that both IL-1β and insulin have potent 
effects on glucose homeostasis and on the immune system further supporting the 
emerging concept of immunometabolism. Understanding the physiological 
synergy between IL-1β and insulin on glucose disposal and macrophage activity 
may have important implications for the development and use of drugs 
modulating IL-1β and insulin actions in pathological conditions. 
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